The National Institutes of Health estimates that there are five million Americans with fibromyalgia.
Dr. Lederman, of Tonix Pharmaceuticals, says that by treating sleep problems in fibromyalgia patients, symptoms of the entire syndrome improve.
He pointed out that opiate addiction is a major problem among chronic pain sufferers and acknowledged that fibromyalgia has not been optimally treated by the medical community.
He added that the growing drug market for fibromyalgia is $1.2 billion a year and that only the U.S. and Canada have approved drugs to treat fibromyalgia.
Only three drugs are indicated for fibromyalgia, none of which have been shown to address the underlying sleep disturbance that is a hallmark of the disorder.
TONIX plans to use a low dose formulation of cyclobenzaprine in a new treatment for fibromyalgia and post-traumatic stress disorder. Cyclobenzaprine is the active ingredient in two prescription muscle relaxants that have been approved by the U.S. Food and Drug Administration and are marketed by other companies.
Read full article.
Find out about my own experiences with cyclobenzaprine here.